These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36652465)

  • 1. Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus.
    Lee K; Lee SK; Lee J; Jeon BK; Kim TH; Yu HT; Lee JM; Park JK; Baek YS; Kim DH; Shim J; Joung B; Lee MH; Pak HN; Park J
    PLoS One; 2023; 18(1):e0280359. PubMed ID: 36652465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.
    Parkash R; Wells GA; Rouleau J; Talajic M; Essebag V; Skanes A; Wilton SB; Verma A; Healey JS; Sterns L; Bennett M; Roux JF; Rivard L; Leong-Sit P; Jensen-Urstad M; Jolly U; Philippon F; Sapp JL; Tang ASL
    Circulation; 2022 Jun; 145(23):1693-1704. PubMed ID: 35313733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design.
    Parkash R; Wells G; Rouleau J; Talajic M; Essebag V; Skanes A; Wilton SB; Verma A; Healey JS; Tang AS
    Am Heart J; 2021 Apr; 234():90-100. PubMed ID: 33472052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure.
    Zhou L; Yang Y; Han W
    Ann Palliat Med; 2021 Oct; 10(10):10887-10895. PubMed ID: 34763450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Pandey AK; Okaj I; Kaur H; Belley-Cote EP; Wang J; Oraii A; Benz AP; Johnson LSB; Young J; Wong JA; Verma S; Conen D; Gerstein H; Healey JS; McIntyre WF
    J Am Heart Assoc; 2021 Sep; 10(17):e022222. PubMed ID: 34459238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.
    Kirchhof P; Breithardt G; Camm AJ; Crijns HJ; Kuck KH; Vardas P; Wegscheider K
    Am Heart J; 2013 Sep; 166(3):442-8. PubMed ID: 24016492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial).
    Osmancik P; Havránek Š; Bulková V; Chovančík J; Roubíček T; Heřman D; Čarná Z; Tuka V; Matoulek M; Fiala M; Jiravský O; Stregl-Hruskova S; Latiňák A; Kotryová J; Jarkovský J
    BMJ Open; 2022 Jun; 12(6):e056522. PubMed ID: 35705334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes.
    Abu-Qaoud MR; Kumar A; Tarun T; Abraham S; Ahmad J; Khadke S; Husami R; Kulbak G; Sahoo S; Januzzi JL; Neilan TG; Baron SJ; Martin D; Nohria A; Reynolds MR; Kosiborod M; Dani SS; Ganatra S
    JACC Clin Electrophysiol; 2023 Oct; 9(10):2109-2118. PubMed ID: 37565953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial.
    Packer DL; Piccini JP; Monahan KH; Al-Khalidi HR; Silverstein AP; Noseworthy PA; Poole JE; Bahnson TD; Lee KL; Mark DB;
    Circulation; 2021 Apr; 143(14):1377-1390. PubMed ID: 33554614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catheter Ablation Versus Best Medical Therapy in Patients With Persistent Atrial Fibrillation and Congestive Heart Failure: The Randomized AMICA Trial.
    Kuck KH; Merkely B; Zahn R; Arentz T; Seidl K; Schlüter M; Tilz RR; Piorkowski C; Gellér L; Kleemann T; Hindricks G
    Circ Arrhythm Electrophysiol; 2019 Dec; 12(12):e007731. PubMed ID: 31760819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure.
    Jones DG; Haldar SK; Hussain W; Sharma R; Francis DP; Rahman-Haley SL; McDonagh TA; Underwood SR; Markides V; Wong T
    J Am Coll Cardiol; 2013 May; 61(18):1894-903. PubMed ID: 23500267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes of Rhythm Control Strategies for Asymptomatic Atrial Fibrillation According to the Quality-of-Life Score: The CODE-AF (Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation) Registry.
    Kim JY; Park HS; Park HW; Choi EK; Park JK; Kim JB; Kang KW; Shim J; Joung B; Park KM
    J Am Heart Assoc; 2022 Sep; 11(18):e025956. PubMed ID: 36073646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of inflammation-mediated myocardial fibrosis on the risk of recurrence after successful ablation of atrial fibrillation - the FIBRO-RISK study: Protocol for a non-randomized clinical trial.
    Korodi S; Toganel R; Benedek T; Hodas R; Chitu M; Ratiu M; Kovacs I; Mester A; Benedek I
    Medicine (Baltimore); 2019 Mar; 98(9):e14504. PubMed ID: 30817568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Sodium-Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity-Score Matching Study and Meta-Analysis.
    Zhao Z; Jiang C; He L; Zheng S; Wang Y; Gao M; Lai Y; Zhang J; Li M; Dai W; Zuo S; Guo X; Li S; Jiang C; Liu N; Tang R; Long D; Du X; Sang C; Dong J; Ma C
    J Am Heart Assoc; 2023 Dec; 12(24):e031269. PubMed ID: 38084708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus.
    Fauchier L; Boriani G; de Groot JR; Kreutz R; Rossing P; Camm AJ
    Europace; 2021 Dec; 23(12):1873-1891. PubMed ID: 34411235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
    Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study.
    Peng Z; Osmanaj F; Yang Y; Hua K; Yang X
    Europace; 2023 Nov; 25(11):. PubMed ID: 37939825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.